Journal of Isfahan Medical School

Journal of Isfahan Medical School

Incidence of Ventilator-Associated Pneumonia at Khorshid and Amin Hospitals in Isfahan, Iran

Document Type : Original Article(s)

Authors
Somayeh Haghighipour, 1
Behrooz Ataei 2
Ali Hedayat 3
1 Assistant Professor of Infectious Diseases, Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
2 Professor of Infectious Diseases, Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
3 School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
10.48305/jims.v43.i841.1602
Abstract
Background: Ventilator-associated pneumonia (VAP) is defined as an infection of the pulmonary parenchyma in patients who have been exposed to invasive mechanical ventilation for at least 48 hours and is a type of intensive care unit (ICU)-acquired pneumonia. VAP is associated with increased morbidity, mortality and costs. Therefore, this study aimed to evaluate the incidence of VAP at Khorshid and Amin hospitals in Isfahan over a two-year period.
Methods: This cross-sectional study was conducted in the intensive care units (ICUs) of Khorshid and Amin hospitals in Isfahan from 2016 to 2018. Data including intubation status and length of stay, mortality, type of bacteria, antibiogram findings, and the incidence of complications were collected from 212 adult patients with pneumonia admitted to the ICU.
Findings: According to our results, the incidence of VAP among pneumonia patients was 27.7%, and the mortality rate was 38.6%. The mean length of hospitalization and intubation were 39.8 and 18.2 days, respectively. The most common microbes isolated from VAP patients were Acinetobacter and Klebsiella. The antibiogram of the isolated strains showed that the most sensitive antibiotics were vancomycin (89.1%), gentamicin (84.2%), and ceftriaxone (67.3%), while the most resistant antibiotic was penicillin (93.9%). Also, 90% of VAP patients experienced complications.
Conclusion: The incidence of VAP and its mortality is high in the studied hospitals. Furthermore, the occurrence of complications due to VAP is very common. Resistance to commonly used antibiotics is likely to require reevaluation of the therapeutic strategies in the studied hospitals.

Highlights

Somayeh Haghighipour: Google Scholar

Behrooz Ataei: Google Scholar

Keywords
Ventilator
Pneumonia
ICU

Subjects

1.     Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63(5): e61-e111.
2.     Papazian L, Klompas M, Luyt C-E. Ventilator-associated pneumonia in adults: a narrative review. Intensive Care Med 2020; 46(5): 888-906.
3.     Park DR. The microbiology of ventilator-associated pneumonia. Respir Care 2005; 50(6): 742-65.
4.     Celis R, Torres A, Gatell JM, Almela M, Rodríguez-Roisin R, Agustí-Vidal A. Nosocomial pneumonia: a multivariate analysis of risk and prognosis. Chest 1988; 93(2): 318-24.
5.     Haley RW, Hooton TM, Culver DH, Stanley RC, Emori TG, Hardison CD, et al. Nosocomial infections in US hospitals, 1975–1976: estimated frequency by selected characteristics of patients. Am J Med 1981; 70(4): 947-59.
6.     Fernando SM, Tran A, Cheng W, Klompas M, Kyeremanteng K, Mehta S, et al. Diagnosis of ventilator-associated pneumonia in critically ill adult patients a systematic review and meta-analysis. Intensive Care Med 2020; 46(6): 1170-9.
7.     Bassi GL, Ferrer M, Marti JD, Comaru T, Torres A. Ventilator-Associated Pneumonia. Semin Respir Crit Care Med 2014; 35(04): 469-81.
8.     Davis KA. Ventilator-associated pneumonia: a review. J Intensive Care Med 2006; 21(4): 211-26.
9.     Koenig SM, Truwit JD. Ventilator-associated pneumonia: diagnosis, treatment, and prevention. Clin Microbiol Rev 2006; 19(4): 637-57.
10.  Kollef MH, Hamilton CW, Ernst FR. Economic impact of ventilator-associated pneumonia in a large matched cohort. Infect Control Hosp Epidemiol 2012; 33(3): 250-6.
11.  Bonell A, Azarrafiy R, Huong VTL, Viet TL, Phu VD, Dat VQ, et al. A systematic review and meta-analysis of ventilator-associated pneumonia in adults in Asia: an analysis of national income level on incidence and etiology. Clin Infect Dis 2019; 68(3): 511-8.
12.  Reignier J, Mercier E, Le Gouge A, Boulain T, Desachy A, Bellec F, et al. Effect of not monitoring residual gastric volume on risk of ventilator-associated pneumonia in adults receiving mechanical ventilation and early enteral feeding: a randomized controlled trial. JAMA 2013; 309(3): 249-56.
13.  Seguin P, Laviolle B, Dahyot-Fizelier C, Dumont R, Veber B, Gergaud S, et al. Effect of oropharyngeal povidone-iodine preventive oral care on ventilator-associated pneumonia in severely brain-injured or cerebral hemorrhage patients: a multicenter, randomized controlled trial. Crit Care Med 2014; 42(1): 1-8.
14.  Hsieh T-C, Hsia S-H, Wu C-T, Lin T-Y, Chang C-C, Wong K-S. Frequency of ventilator-associated pneumonia with 3-day versus 7-day ventilator circuit changes. Pediatr Neonatol 2010; 51(1): 37-43.
15.  Emonet S, Lazarevic V, Leemann Refondini C, Gaïa N, Leo S, Girard M, et al. Identification of respiratory microbiota markers in ventilator-associated pneumonia. Intensive Care Med 2019; 45(8): 1082-92.
16.  Charles MP, Kali A, Easow JM, Joseph NM, Ravishankar M, Srinivasan S, et al. Ventilator-associated pneumonia. Australas Med J 2014; 7(8): 334-44.
17.  Barbier F, Andremont A, Wolff M, Bouadma L. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med 2013; 19(3): 216-28.
18.  Rosenthal VD, Maki DG, Graves N. The International Nosocomial Infection Control Consortium (INICC): goals and objectives, description of surveillance methods, and operational activities. Am J Infect Control 2008; 36(9): e1-e12.
19.  Bouadma L, Sonneville R, Garrouste-Orgeas M, Darmon M, Souweine B, Voiriot G, et al. Ventilator-associated events: prevalence, outcome, and relationship with ventilator-associated pneumonia. Crit Care Med 2015; 43(9): 1798-806.
20.  Dietrich ES, Demmler M, Schulgen G, Fekec K, Mast O, Pelz K, et al. Nosocomial pneumonia: a cost-of-illness analysis. Infection 2002; 30(2): 61-7.
21.  Warren DK, Shukla SJ, Olsen MA, Kollef MH, Hollenbeak CS, Cox MJ, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003; 31(5): 1312-7.
22.  Melsen WG, Rovers MM, Groenwold RH, Bergmans DC, Camus C, Bauer TT, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis 2013; 13(8): 665-71.
23.  Ali HS, Khan FY, George S, Shaikh N, Al-Ajmi J. Epidemiology and Outcome of Ventilator-Associated Pneumonia in a Heterogeneous ICU Population in Qatar. Biomed Res Int 2016; 2016: 8231787.
24.  Sosa-Hernández O, Matías-Téllez B, Estrada-Hernández A, Cureño-Díaz MA, Bello-López JM. Incidence and costs of ventilator-associated pneumonia in the adult intensive care unit of a tertiary referral hospital in Mexico. Am J Infect Control 2019; 47(9): e21-e5.
25.  Osman S, Al Talhi YM, AlDabbagh M, Baksh M, Osman M, Azzam M. The incidence of ventilator-associated pneumonia (VAP) in a tertiary-care center: comparison between pre-and post-VAP prevention bundle. J Infect Public Health 2020; 13(4): 552-7.
26.  Elliott D, Elliott R, Burrell A, Harrigan P, Murgo M, Rolls K, et al. Incidence of ventilator-associated pneumonia in Australasian intensive care units: use of a consensus-developed clinical surveillance checklist in a multisite prospective audit. BMJ Open 2015; 5(10): e008924.
27.  Trouillet J-L, Chastre J, Vuagnat A, Joly-Guillou M-L, Combaux D, Dombret M-C, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157(2): 531-9.
28.  Ferrer M, Liapikou A, Valencia M, Esperatti M, Theessen A, Martinez JA, et al. Validation of the American Thoracic Society-Infectious Diseases Society of America guidelines for hospital-acquired pneumonia in the intensive care unit. Clin Infect Dis 2010; 50(7): 945-52.
29.  Martin-Loeches I, Deja M, Koulenti D, Dimopoulos G, Marsh B, Torres A, et al. Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. Intensive Care Med 2013; 39(4): 672-81.
30.  Martin-Loeches I, Povoa P, Rodríguez A, Curcio D, Suarez D, Mira J-P, et al. Incidence and prognosis of ventilator-associated tracheobronchitis (TAVeM): a multicentre, prospective, observational study. Lancet Respir Med 2015; 3(11): 859-68.
31.  Restrepo MI, Peterson J, Fernandez JF, Qin Z, Fisher AC, Nicholson SC. Comparison of the bacterial etiology of early-onset and late-onset ventilator-associated pneumonia in subjects enrolled in 2 large clinical studies. Respir Care 2013; 58(7): 1220-5.
32.  Timsit J-F, Pilmis B, Zahar J-R, editors. How should we treat hospital-acquired and ventilator-associated pneumonia caused by extended-spectrum β-lactamase producing Enterobacteriaceae? Semin Respir Crit Care Med 2017; 38(3): 287-300.
 
Journal of Isfahan Medical School
Volume 43, Issue 841
1st Week , February
January and February 2026
Pages 1602-1606

  • Receive Date 25 March 2025
  • Accept Date 31 August 2025